| Year |
Citation |
Score |
| 2019 |
Porter RL, Magnus NKC, Thapar V, Morris R, Szabolcs A, Neyaz A, Kulkarni AS, Tai E, Chougule A, Hillis A, Golczer G, Guo H, Yamada T, Kurokawa T, Yashaswini C, et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31843922 DOI: 10.1073/Pnas.1914915116 |
0.31 |
|
| 2013 |
Porter RL, Georger MA, Bromberg O, McGrath KE, Frisch BJ, Becker MW, Calvi LM. Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury. Stem Cells (Dayton, Ohio). 31: 372-83. PMID 23169593 DOI: 10.1002/Stem.1286 |
0.79 |
|
| 2012 |
Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, Calvi LM. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood. 120: 303-13. PMID 22596259 DOI: 10.1182/Blood-2011-09-377853 |
0.787 |
|
| 2012 |
Frisch BJ, Shafiq I, Porter RL, Weber JM, Smith JN, Bromberg O, Basil M, Dhillon RS, Schwarz EM, Calvi LM. Intermittent in Vivo Parathyroid Hormone (PTH) Treatment Results in Jagged 1 (Jag 1) Dependent and Independent Effects On Hematopoietic Stem Cells (HSCs) Blood. 120: 642-642. DOI: 10.1182/Blood.V120.21.642.642 |
0.783 |
|
| 2011 |
Porter RL, Georger MA, Calvi LM. Prostaglandin E2 Inhibits Apoptosis in Hematopoietic Stem and Progenitor Cells and Enhances Their Survival Following Sub-Lethal Radiation Injury, Blood. 118: 3401-3401. DOI: 10.1182/Blood.V118.21.3401.3401 |
0.764 |
|
| 2010 |
Porter RL, Calvi LM. Prostaglandin E2 Is Rapidly Produced In Response to Bone Marrow Injury and Improves Survival of Primitive Hematopoietic Cells Blood. 116: 407-407. DOI: 10.1182/Blood.V116.21.407.407 |
0.769 |
|
| 2009 |
Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood. 114: 4054-63. PMID 19726721 DOI: 10.1182/Blood-2009-03-205823 |
0.807 |
|
| 2009 |
Porter RL, Calvi LM. Key endothelial signals required for hematopoietic recovery. Cell Stem Cell. 4: 187-8. PMID 19265650 DOI: 10.1016/J.Stem.2009.02.005 |
0.701 |
|
| 2009 |
Weber JM, Frisch BJ, Porter RL, Bromberg O, Olm-shipman AJ, Awad H, Calvi LM. In Vivo Parathyroid Hormone Treatment Expands All Multipotent Primitive Hematopoietic Cell Subsets. Blood. 114: 1449-1449. DOI: 10.1182/Blood.V114.22.1449.1449 |
0.799 |
|
| 2008 |
Frisch BJ, Porter RL, Calvi LM. Hematopoietic niche and bone meet. Current Opinion in Supportive and Palliative Care. 2: 211-7. PMID 18685423 DOI: 10.1097/Spc.0B013E32830D5C12 |
0.774 |
|
| 2008 |
Porter RL, Calvi LM. Communications between bone cells and hematopoietic stem cells. Archives of Biochemistry and Biophysics. 473: 193-200. PMID 18410740 DOI: 10.1016/J.Abb.2008.04.001 |
0.746 |
|
| 2008 |
McGrath KE, Kingsley PD, Koniski AD, Porter RL, Bushnell TP, Palis J. Enucleation of primitive erythroid cells generates a transient population of "pyrenocytes" in the mammalian fetus. Blood. 111: 2409-17. PMID 18032705 DOI: 10.1182/Blood-2007-08-107581 |
0.364 |
|
| 2008 |
Porter RL, Frisch BJ, O’Keefe RJ, Calvi LM. Prostaglandin E2 (PGE2) Treatment Rapidly Increases the Fraction of Non-Dividing Hematopoietic Stem Cells (HSCs) Blood. 112: 73-73. DOI: 10.1182/Blood.V112.11.73.73 |
0.806 |
|
| 2007 |
Frisch BJ, Weber JM, Porter RL, Gigliotti BJ, Smith JN, Olm-Shipman AJ, O’Keefe RJ, Jordan CT, Calvi LM. In Vivo Treatment with Prostaglandin E2 (PGE2) Selectively Expands Short-Term Hematopoietic Stem Cells. Blood. 110: 1254-1254. DOI: 10.1182/Blood.V110.11.1254.1254 |
0.793 |
|
| Show low-probability matches. |